AU2021223336B2 - Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof - Google Patents
Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereofInfo
- Publication number
- AU2021223336B2 AU2021223336B2 AU2021223336A AU2021223336A AU2021223336B2 AU 2021223336 B2 AU2021223336 B2 AU 2021223336B2 AU 2021223336 A AU2021223336 A AU 2021223336A AU 2021223336 A AU2021223336 A AU 2021223336A AU 2021223336 B2 AU2021223336 B2 AU 2021223336B2
- Authority
- AU
- Australia
- Prior art keywords
- prodrug
- lipid
- liposome
- slnp
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062995887P | 2020-02-19 | 2020-02-19 | |
| US62/995,887 | 2020-02-19 | ||
| PCT/US2021/010005 WO2021167703A1 (en) | 2020-02-19 | 2021-02-19 | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021223336A1 AU2021223336A1 (en) | 2022-10-06 |
| AU2021223336B2 true AU2021223336B2 (en) | 2026-07-02 |
Family
ID=75223393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021223336A Active AU2021223336B2 (en) | 2020-02-19 | 2021-02-19 | Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof |
| AU2024339588A Pending AU2024339588A1 (en) | 2020-02-19 | 2024-05-13 | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024339588A Pending AU2024339588A1 (en) | 2020-02-19 | 2024-05-13 | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11801304B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4096716A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7842690B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220143063A (cg-RX-API-DMAC7.html) |
| CN (3) | CN121287708A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021223336B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170142A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021167703A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7842690B2 (ja) * | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
| CN112669958B (zh) * | 2020-12-08 | 2022-09-09 | 河北医科大学第二医院 | 代谢物作为疾病诊断的生物标志物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2409708A1 (en) * | 2010-07-21 | 2012-01-25 | B & G Partners, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| WO2013082389A1 (en) * | 2011-11-30 | 2013-06-06 | Mallinckrodt Inc. | Mmp-targeted therapeutic and/or diagnostic nanocarriers |
| WO2015166498A1 (en) * | 2014-05-02 | 2015-11-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pt (iv) derivatives and nanocarriers comprising them |
| CN106176609A (zh) * | 2016-08-22 | 2016-12-07 | 李因传 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
| EP3276003A1 (en) * | 2015-03-27 | 2018-01-31 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539748A1 (en) * | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| WO2006031471A2 (en) | 2004-09-01 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Liposomal vectors |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| CA2632799A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| PT104158B (pt) | 2008-08-18 | 2011-02-24 | Univ Do Minho | Aplicação da monooleína como novo lípido adjuvante em lipofecção |
| MX389666B (es) | 2009-10-16 | 2025-03-19 | Scripps Research Inst | Induccion de celulas pluripotentes. |
| US20130189780A1 (en) | 2009-12-31 | 2013-07-25 | Fate Therapeutics, Inc. | Reprogramming compositions |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| CN103857384B (zh) | 2011-06-06 | 2017-07-11 | 大学健康网络 | 用于合成卟啉‑磷脂结合物的方法 |
| CN104023749B (zh) | 2011-09-14 | 2019-12-17 | 西北大学 | 能穿过血脑屏障的纳米缀合物 |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| CA2874490C (en) * | 2012-05-23 | 2021-11-16 | The Ohio State University | Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| AU2014278178B2 (en) | 2013-06-11 | 2021-01-21 | President And Fellows Of Harvard College | SC-beta cells and compositions and methods for generating the same |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016149756A1 (en) * | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| WO2018081480A1 (en) * | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| IL268995B2 (en) | 2017-03-02 | 2024-02-01 | Nat Res Council Canada | TGF-B receptor ectodomain fusion compounds and their uses |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| CA3063932A1 (en) | 2017-05-18 | 2018-11-12 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| US11046729B2 (en) | 2017-10-26 | 2021-06-29 | Southern Research Institute | Dipeptide analogs as TGF-beta inhibitors |
| AU2018431586B2 (en) | 2018-07-09 | 2025-03-20 | Synthis Therapeutics, Inc | Antibody-ALK5 inhibitor conjugates and their uses |
| US12448475B2 (en) * | 2019-06-21 | 2025-10-21 | The University Of North Carolina At Chapel Hill | Drug delivery compositions and applications thereof |
| JP7842690B2 (ja) * | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
-
2021
- 2021-02-19 JP JP2022549457A patent/JP7842690B2/ja active Active
- 2021-02-19 AU AU2021223336A patent/AU2021223336B2/en active Active
- 2021-02-19 KR KR1020227031715A patent/KR20220143063A/ko active Pending
- 2021-02-19 CA CA3170142A patent/CA3170142A1/en active Pending
- 2021-02-19 CN CN202511406387.5A patent/CN121287708A/zh active Pending
- 2021-02-19 US US17/300,063 patent/US11801304B2/en active Active
- 2021-02-19 WO PCT/US2021/010005 patent/WO2021167703A1/en not_active Ceased
- 2021-02-19 EP EP21714458.3A patent/EP4096716A1/en active Pending
- 2021-02-19 CN CN202180019109.8A patent/CN115243724B/zh active Active
-
2023
- 2023-07-10 US US18/445,323 patent/US20240050575A1/en active Pending
-
2024
- 2024-05-13 KR KR1020267003654A patent/KR20260035240A/ko active Pending
- 2024-05-13 US US18/831,041 patent/US20250032620A1/en active Pending
- 2024-05-13 EP EP24733354.5A patent/EP4743119A1/en active Pending
- 2024-05-13 AU AU2024339588A patent/AU2024339588A1/en active Pending
- 2024-05-13 CN CN202480045094.6A patent/CN121487753A/zh active Pending
-
2025
- 2025-11-26 JP JP2025204012A patent/JP2026032152A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2409708A1 (en) * | 2010-07-21 | 2012-01-25 | B & G Partners, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| WO2013082389A1 (en) * | 2011-11-30 | 2013-06-06 | Mallinckrodt Inc. | Mmp-targeted therapeutic and/or diagnostic nanocarriers |
| WO2015166498A1 (en) * | 2014-05-02 | 2015-11-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pt (iv) derivatives and nanocarriers comprising them |
| EP3276003A1 (en) * | 2015-03-27 | 2018-01-31 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| CN106176609A (zh) * | 2016-08-22 | 2016-12-07 | 李因传 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| MURA SIMONA; BUI DUC TRUNG; COUVREUR PATRICK; NICOLAS JULIEN: "Lipid prodrug nanocarriers in cancer therapy", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, NL, vol. 208, 21 January 2015 (2015-01-21), NL, pages 25 - 41, XP029158890, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.01.021 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20260035240A (ko) | 2026-03-12 |
| CN115243724A (zh) | 2022-10-25 |
| EP4743119A1 (en) | 2026-05-20 |
| JP2026032152A (ja) | 2026-02-25 |
| AU2024339588A1 (en) | 2026-02-26 |
| US20240050575A1 (en) | 2024-02-15 |
| CN121287708A (zh) | 2026-01-09 |
| US20250032620A1 (en) | 2025-01-30 |
| CN121487753A (zh) | 2026-02-06 |
| CN115243724B (zh) | 2025-10-21 |
| AU2021223336A1 (en) | 2022-10-06 |
| CA3170142A1 (en) | 2021-08-26 |
| JP2023514324A (ja) | 2023-04-05 |
| JP7842690B2 (ja) | 2026-04-08 |
| EP4096716A1 (en) | 2022-12-07 |
| KR20220143063A (ko) | 2022-10-24 |
| US11801304B2 (en) | 2023-10-31 |
| WO2021167703A1 (en) | 2021-08-26 |
| US20210260197A1 (en) | 2021-08-26 |